Oncocyte Corp Quarterly Nonoperating Income (Expense) in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Oncocyte Corp quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2015 to Q3 2024.
  • Oncocyte Corp Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $22K, a 8.33% decline year-over-year.
  • Oncocyte Corp Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $449K.
  • Oncocyte Corp annual Nonoperating Income (Expense) for 2023 was $281K.
  • Oncocyte Corp annual Nonoperating Income (Expense) for 2022 was -$615K, a 172% decline from 2021.
  • Oncocyte Corp annual Nonoperating Income (Expense) for 2021 was $854K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $449K $22K -$2K -8.33% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $451K $102K +$141K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $310K $138K +$29K +26.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $281K $187K +$556K Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$275K $24K +$136K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$411K -$39K -$301K -115% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$110K $109K +$505K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$615K -$369K -$261K -242% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-16
Q3 2022 -$354K -$112K +$84K +42.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$438K $262K -$1.02M -79.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $581K -$396K -$273K -222% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $854K -$108K +$93K +46.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-11
Q3 2021 $761K -$196K +$343K +63.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $418K $1.28M +$1.62M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$1.2M -$123K +$273K +68.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$1.48M -$201K +$230K +53.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$1.71M -$539K -$571K -1784% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-11
Q2 2020 -$1.14M -$340K -$419K -530% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-11
Q1 2020 -$716K -$396K -$529K -398% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-11
Q4 2019 -$187K -$431K +$22K +4.86% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-19
Q3 2019 -$209K $32K -$20K -38.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$189K $79K +$358K Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
Q1 2019 -$547K $133K +$5K +3.91% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$552K -$453K -$385K -566% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 -$167K $52K +$123K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$290K -$279K -$64K -29.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$226K $128K +$300K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$526K -$68K -$60K -750% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$466K -$71K -$58K -446% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$408K -$215K -$204K -1855% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$204K -$172K -$176K -4400% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$28K -$8K -$9K -900% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$19K -$13K -$3K -30% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-14
Q2 2016 -$16K -$11K -$5K -83.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$11K $4K +$6K Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-28
Q4 2015 -$17K $1K Oct 1, 2015 Dec 31, 2015 10-K 2018-04-02
Q3 2015 -$10K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$6K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$2K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.